Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01628198 · ClinicalTrials.gov registry record · NA
Impact of Renal SympAthetic DenerVation on Chronic HypErtension
A NA study, sponsored by Vivek Reddy.
- Terminated
- Registry status
- NA
- Development phase
- 38
- Enrollment target
NCT01628198: Clinical Trial NA study, sponsored by Vivek Reddy.
NCT01628198 is a NA study that was terminated before completion, run by Vivek Reddy. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01628198, a NA study, was terminated before completion, sponsored by Vivek Reddy.
- TERMINATED
- Registry status
- NA
- Development phase
- 38 participants
- Enrollment target
Study Summary
Despite the development of many drug therapies designed to treat high blood pressure (hypertension), it remains a considerable and poorly managed health, social and economic burden. For various reasons, including the high health care costs of treatment, there are estimates that up to 65% of patients with high blood pressure have untreated and/or uncontrolled blood pressure (BP). Aside from its effect on kidney function, chronic high blood pressure increases the risk for stroke, and heart disease. It is also thought to be involved in the formation of irregular heartbeats. This link between high blood pressure and heart health has been well described, as has their combined effect on the aging and the obesity-battling Western world. A recently published study (Symplicity HTN-2 trial) established the benefit of a new treatment procedure, catheter-based renal sympathetic denervation (RSDN) for hypertension, as having enormous potential for the treatment of patients with high blood pressure. This multi-center trial will attempt to confirm and expand on these promising data. Patients who enroll in the trial will be followed for 4 years.
Primary Outcome
The change in systolic blood pressure as measured by 24 hour ambulatory monitoring at 6 months as compared to from baseline.
Interventions
- DEVICE Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-08 |
| Phase | NA |
Why NCT01628198 stopped before completion
NCT01628198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter is the first listed.
NCT01628198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01628198 about?
NCT01628198 is a clinical study titled "Impact of Renal SympAthetic DenerVation on Chronic HypErtension". Despite the development of many drug therapies designed to treat high blood pressure (hypertension), it remains a considerable and poorly managed health, social and economic burden. For various reasons, including the high health care costs of treatment, there are estimates that up to 65% of patients...
What is the current status of trial NCT01628198?
This trial is currently terminated. It is a NA study. The enrollment target is 38 participants. The study started on 2011-10. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01628198?
The interventions under investigation include: Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter (DEVICE).
Who is sponsoring clinical trial NCT01628198?
This trial is sponsored by Vivek Reddy, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01628198's enrollment target sits among peer trials
38 1538th of 2000 higher than 461 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia